Psyence Biomedical(PBM.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Psyence Biomedical
PBM.US
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care.
1.971 T
PBM.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 | PBM Stock News

    Psyence Biomedical Ltd. (Nasdaq: PBM) has announced the adjournment of its annual and special shareholder meeting to February 12, 2026, due to insufficient quorum. The meeting will take place at 9:00 a.m. New York Time in Cape Town, South Africa. The record date remains unchanged as of December 23, 2025. The company is working with proxy agents to ensure quorum is met for the reconvened meeting. Psyence BioMed specializes in psychedelic-based therapeutics and aims to address unmet mental health needs.

    StockTitan·
    US
    PBM
    +22.01%
    StockTitan·
    US
    PBM
    +22.01%

    Psyence BioMed delays reverse stock split effective date announcement, Nasdaq: PBM stock impacted.

    On January 20, 2026, Psyence Biomedical Ltd. (Nasdaq: PBM) disclosed the decision to delay the planned effective date of its reverse stock split for its common stock. The company, referred to as Psyence BioMed, opted to postpone this action affecting its issued and outstanding common stock shares.

    Unusual Whales·
    US
    SBIO
    -2.09%
    US
    PBE
    -1.08%
    US
    BIB
    -3.33%
    Unusual Whales·
    US
    SBIO
    -2.09%
    US
    PBE
    -1.08%
    US
    BIB
    -3.33%

    Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | PBM Stock News

    Psyence Biomedical Ltd. has postponed the effective date of its previously announced reverse stock split of 1-for-6.25, originally set for January 20, 2026. The decision follows further internal consideration, and the company will issue a new press release with a revised effective date. Until then, shares will continue to trade on Nasdaq under the ticker "PBM" without adjustment. The Board retains discretion over the timing of the split.

    StockTitan·
    US
    FBT
    -1.23%
    US
    BBH
    -1.27%
    US
    BIB
    -3.33%
    StockTitan·
    US
    FBT
    -1.23%
    US
    BBH
    -1.27%
    US
    BIB
    -3.33%

    Psyence BioMed implements 1-for-6.25 reverse stock split on Jan. 14, 2026, following special resolution.

    Psyence Biomedical Ltd. announced on Jan. 14, 2026, that their 1-for-6.25 share consolidation (reverse stock split) has become effective. The decision was made after shareholders approved a special resolution on April 16, 2025, allowing the Board of Directors to implement a share consolidation at a ratio of up to 1-for-50. Initially, the Board set a 1-for-7.97 consolidation ratio on May 5, 2025. Following this, a second share consolidation at a ratio of 1-for-6.25 was approved on December 4, 2025. The company's Nasdaq symbol is PBM.

    Unusual Whales·
    US
    PBM
    +22.01%
    Unusual Whales·
    US
    PBM
    +22.01%

    Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | PBM Stock News

    Psyence Biomedical Ltd. announced a 1-for-6.25 reverse stock split effective January 20, 2026. This follows shareholder approval for a consolidation ratio of up to 1-for-50. The company's common shares will trade under the symbol "PBM" on Nasdaq, with a new CUSIP number. Post-consolidation, the number of shares will decrease from 6,388,604 to 1,022,177. Fractional shares will be rounded, and shareholders are advised to contact their brokers for details. Psyence BioMed focuses on psychedelic-based therapeutics for mental health.

    StockTitan·
    US
    PBM
    +22.01%
    StockTitan·
    US
    PBM
    +22.01%
    © 2026 Longbridge｜Disclaimer